Basualdo-Sigales MC, Alcántara-Pérez PA, Soler-Claudín C

Language: Spanish
References: 14
Page: 122-127
PDF size: 93.16 Kb.

ABSTRACT

The aim of this study was to evaluate the sensitivity and specificity of the third generation ELISA for qualitative determination of hepatitis B surface antigen (HbsAg) in human plasma or serum: ImmunoLISATM HBsAg 1 Step by Orgenics LTD. We use a panel of 200 pre-evaluated plasmas with UMELISA HBs Ag PLUS by Centro de Inmunoensayo de la Habana Cuba. Assay protocols were followed according the manufacturer. All twice positive samples were assayed for confirmatory test. The assay showed 100% specificity, 96.3% sensitivity, 100% positive predictive value and 99.43% negative predictive value. Our results support the use of this assay as a screening test for hepatitis B and as is suggested for all screening test a confirmatory assay must be performed a assure accurate results.

REFERENCES

1. World Health Organization. Hepatitis B. (Fact sheet no. 204.) Geneva, Switzerland: World Health Organization; 2000.

2. Silveira TR, Fonseca JC, Rivera L. Hepatitis B seroprevalence in Latin America. Rev Panam Salud Publica. 1999; 6: 378-83.

3. Ayala-Gaytán JJ, Guerra-Avalos FJ, Mora-Brondo P. Prevalence of viral markers for hepatitis B, C and human immunodeficiency virus in volunteer blood donors in Northeast Mexico. Rev Gastroenterol Mex. 1997; 62: 250-3.

4. Carreto-Vélez MA, Carrada-Bravo T, Martínez-Magdaleno A. Seroprevalence of HBV, HCV, and HIV among blood donors in Irapuato, Mexico. Salud Publica Mex. 2003; 45(Supl 5): S690-3.

5. Rivera-López MR, Zavala-Méndez C, Arenas-Esqueda A. Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors. Gac Med Mex. 2004; 140: 657-60.

6. Coleman PF. Detecting hepatitis B surface antigen mutants. Emerg Infect Dis. 2006; 12: 198-203.

7. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007; 20: 428.

8. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985; 151: 599-603.

9. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006; 43: S173-S181.

10. Mast EE, Margolis HS, Fiore AE. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005; 54(RR-16): 1-31.

11. Guidotti LG, Matzke B, Pasquinelli C, Shoenberger JM, Rogler CE, Chisari FE. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol. 1996; 70: 7056-61.

12. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schroder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol. 1993; 67: 3756-62.

13. Carman W F, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B antigen in patients with chronic hepatitis B infection. Lancet. 1989; 334: 588-91.

14. Louisirirotchanakul S, Kanoksinsombat C, O’Charoen R, Fongsatikul L, Paupairoj C, Lulitanond V, et al. HBsAg diagnostic kits in the detection of hepatitis B virus mutation within "a" determinant. Viral Immunol. 2006; 19: 108-14.